Jin Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jin Gao has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bing-Cheng Zhao
Department of Anaesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication - Chen Chen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.
1 shared publication - Fang Yan
Department of Radiation Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.
1 shared publication - Gang Chen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.
1 shared publication - Lu-Jun Shen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.
1 shared publication - Meng-Kun Chen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.
1 shared publication
Latest Publications
- Open Access
- 5 March 2015
- Published by Springer Nature in Chinese Journal of Cancer
- Vol. 34 (3) , 1-10
Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients
Thrombocytosis has been identified as an unfavorable prognostic factor in several types of cancer. This study aimed to evaluate the prognostic value of pretreatment platelet count in association with the TNM staging system and therapeutic regimens in patients with nasopharyngeal carcinoma (NPC). A total of 2,626 patients with NPC were retrospectively analyzed. Platelet count >300 × 109/L was defined as thrombocytosis. Matched-pair analysis was performed between patients receiving chemoradiotherapy and radiotherapy. Multivariate analysis showed that platelet count was an independent unfavorable prognostic factor for overall survival (OS) [hazard ratio (HR) = 1.810, 95% confidence interval (CI) = 1.531–2.140, P < 0.001] and distant metastasis–free survival (DMFS) (HR = 1.873, 95% CI = 1.475–2.379, P < 0.001) in the entire patient cohort. Further subgroup analysis revealed that increased platelet count was an independent unfavorable prognostic factor for OS and DMFS in patients with NPC stratified by early and advanced T category, N category, or TNM classification (all P ≤ 0.001). Receiver operating characteristic (ROC) curves verified that the predictive value of TNM classification for OS was improved when combined with pretreatment platelet count (P = 0.030). Matched-pair analysis showed that chemoradiotherapy significantly improved OS only in advanced-stage NPC with thrombocytosis (HR = 0.416, 95% CI = 0.226–0.765, P = 0.005). Pretreatment platelet count, when combined with TNM classification, is a useful indicator for metastasis and survival in patients with NPC. It may improve the predictive value of the TNM classification and help to identify patients likely to benefit from more aggressive therapeutic regimens.
- 5 March 2015
- Published by Springer Nature in Chinese Journal of Cancer
- Vol. 34 (3) , 1-10
Open AccessPretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients
Thrombocytosis has been identified as an unfavorable prognostic factor in several types of cancer. This study aimed to evaluate the prognostic value of pretreatment platelet count in association with the TNM staging system and therapeutic regimens in patients with nasopharyngeal carcinoma (NPC). A total of 2,626 patients with NPC were retrospectively analyzed. Platelet count >300 × 109/L was defined as thrombocytosis. Matched-pair analysis was performed between patients receiving chemoradiotherapy and radiotherapy. Multivariate analysis showed that platelet count was an independent unfavorable prognostic factor for overall survival (OS) [hazard ratio (HR) = 1.810, 95% confidence interval (CI) = 1.531–2.140, P < 0.001] and distant metastasis–free survival (DMFS) (HR = 1.873, 95% CI = 1.475–2.379, P < 0.001) in the entire patient cohort. Further subgroup analysis revealed that increased platelet count was an independent unfavorable prognostic factor for OS and DMFS in patients with NPC stratified by early and advanced T category, N category, or TNM classification (all P ≤ 0.001). Receiver operating characteristic (ROC) curves verified that the predictive value of TNM classification for OS was improved when combined with pretreatment platelet count (P = 0.030). Matched-pair analysis showed that chemoradiotherapy significantly improved OS only in advanced-stage NPC with thrombocytosis (HR = 0.416, 95% CI = 0.226–0.765, P = 0.005). Pretreatment platelet count, when combined with TNM classification, is a useful indicator for metastasis and survival in patients with NPC. It may improve the predictive value of the TNM classification and help to identify patients likely to benefit from more aggressive therapeutic regimens.